Augmentation of antitumor activity of 5-fluorouracil by interferon α is associated with up-regulation of p27(Kip1) in human hepatocellular carcinoma cells

Clinical Cancer Research

Volumn 6, Issue 7, 2000, Pages 2881-2890

  Eguchi, Hidetoshi ^a   Nagano, Hiroaki ^a   Yamamoto, Hirofumi ^a   Miyamoto, Atsushi ^a   Kondo, Motoi ^a   Dono, Keizo ^a   Nakamori, Shoji ^a   Umeshita, Koji ^a   Sakon, Masato ^a   Monden, Morito ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; PROTEIN P27; RECOMBINANT ALPHA INTERFERON;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; DRUG POTENTIATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CDC2-CDC28 KINASES; CELL CYCLE; CELL CYCLE PROTEINS; CELL DIVISION; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; DRUG SYNERGISM; FLOW CYTOMETRY; FLUOROURACIL; HUMANS; IN SITU NICK-END LABELING; INTERFERON-ALPHA; KINETICS; LIVER NEOPLASMS; MEMBRANE PROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; PROTEIN-SERINE-THREONINE KINASES; RECEPTOR, INTERFERON ALPHA-BETA; RECEPTORS, INTERFERON; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 0033941539     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Farmer, D. G., Rosove, M. H., Shaked, A., and Busuttil, R. W. Current treatment modalities for hepatocellular carcinoma. Ann. Surg., 219: 236-247, 1994.
2. Sangro, B., Herraiz, M., Martinez, G. M. A., Bilbao, I., Herrero, I., Beloqui, O., Betes, M., de la, Pena, A., Cienfuegos, J. A., Quiroga, J., and Prieto, J. Prognosis of hepatocellular carcinoma in relation to treatment: a multivariate analysis of 178 patients from a single European institution. Surgery, 124: 575-583, 1998.
3. Stuart, K. E., Anand, A. J., and Jenkins, R. L. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer (Phila.), 77: 2217-2222, 1996.
4. Urabe, T., Kaneko, S., Matsushita, E., Unoura, M., and Kobayashi, K. Clinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin and subcutaneous interferon-α-2b for patients with locally advanced hepatocellular carcinoma. Oncology, 55: 39-47, 1998.
5. Leung, T. W., Patt, Y. Z., Lau, W. Y., Ho, S. K., Yu, S. C., Chan, A. T., Mok, T. S., Yeo, W., Liew, C. T., Leung, N. W., Tang, A. M., and Johnson, P. J. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin. Cancer Res., 5: 1676-1681, 1999.
6. Patt, Y. Z., Yoffe, B., Charnsangavej, C., Pazdur, R., Fischer, H., Cleary, K., Roh, M., Smith, R., Noonan, C. A., and Levin, B. Low serum α-feto-protein level in patients with hepatocellular carcinoma as a predictor of response to 5-FU and interferon-α-2b. Cancer (Phila.), 72: 2574-2582, 1993.
7. Wadler, S., Schwartz, E. L., Goldman, M., Lyver, A., Itri, L., and Wiernik, P. H. Preclinical and clinical studies of 5-fluorouracil (FURA) and recombinant α-2a-interferon (IFN) against gastrointestinal (GI) malignancies. Clin. Res., 36: 803A, 1988.
8. Wadler, S., Schwartz, E. L., Goldman, M., Lyver, A., Rader, M., Zimmerman, M., Itri, L., Weinberg, V., and Wiernik, P. H. Fluorouracil and recombinant α-2a-interferon: an active regimen against advanced colorectal carcinoma. J. Clin. Oncol., 7: 1769-1775, 1989.
9. Wadler, S., and Schwartz, E. L. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res., 50: 3473-3486, 1990.
10. Greenblatt, M. S., Mangalik, A., Ferguson, J., and Elias, L. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon α. Clin. Cancer Res., 1: 615-620, 1995.
11. Kelsen, D., Lovett, D., Wong, J., Saltz, L., Buckley, M., Murray, P., Heelan, R., and Lightdale, C. Interferon α-2a and fluorouracil in the treatment of patients with advanced esophageal cancer. J. Clin. Oncol., 10: 269-274, 1992.
12. Lee, K. H., Lee, J. S., Suh, C., Lee, Y. S., Min, Y. I., Ahn, S. H., Park, K. C., Kim, S. K., and Kim, S. H. Combination of 5-fluorouracil and recombinant interferon α-2B in advanced gastric cancer. A Phase I study. Am. J. Clin. Oncol., 15: 141-145, 1992.
13. Stuart, K., Tessitore, J., and Huberman, M. 5-Fluorouracil and α-interferon in hepatocellular carcinoma. Am. J. Clin. Oncol., 19: 136-139, 1996.
14. Greco, F. A., Figlin, R., York, M., Einhorn, L., Schilsky, R., Marshall, E. M., Buys, S. S., Froimtchuk, M. J., Schuller, J., Schlichter, L., Buyse, M., Ritter, L., Man, A., and Yap, A. K. Phase III randomized study to compare interferon α-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. J. Clin. Oncol., 14: 2674-2681, 1996.
15. Pazdur, R., Ajani, J. A., Winn, R., Bearden, J., Belt, R. J., Pilat, S., Hallinan, R., and Levin, B. A Phase II trial of 5-fluorouracil and recombinant α-2a-interferon in previously untreated metastatic gastric carcinoma. Cancer (Phila.), 69: 878-882, 1992.
16. John, W. J., and Flett, M. Q. Continuous venous infusion 5-fluorouracil and interferon-α in pancreatic carcinoma. Am. J. Clin. Oncol., 21: 147-150, 1998.
17. Schwartz, E. L., Hoffman, M., O'Connor, C. J., and Wadler, S. Stimulation of 5-fluorouracil metabolic activation by interferon-α in human colon carcinoma cells. Biochem. Biophys. Res. Commun., 182: 1232-1239, 1992.
18. Elias, L., and Sandoval, J. M. Interferon effects upon fluorouracil metabolism by HL-60 cells. Biochem. Biophys. Res. Commun., 163: 867-874, 1989.
19. Matheson, D. S., Green, B. J., Friedman, S. J., and Hoar, D. I. Studies on the mechanism of activation of human natural killer function by interferon and inhibitors of thymidylate synthesis. Cell Immunol., 111: 118-125, 1988.
20. Horowitz, R. W., Heerdt, B. G., Hu, X., Schwartz, E. L., and Wadler, S. Combination therapy with 5-fluorouracil and IFN-α2a induces a nonrandom increase in DNA fragments of less than 3 megabases in HT29 colon carcinoma cells. Clin. Cancer Res., 3: 1317-1322, 1997.
21. Sabaawy, H. E., Farley, T., Ahmed, T., Feldman, E., and Abraham, N. G. Synergetic effects of retrovirus IFN-α gene transfer and 5-FU on apoptosis of colon cancer cells. Acta Haematol., 101: 82-88, 1999.
22. Kountouras, J., Boura, P., Karolides, A., Zaharioudaki, E., and Tsapas, G. Recombinant a2 interferon (a-IFN) with chemo-hormonal therapy in patients with hepatocellular carcinoma (HCC). Hepatogastroenterology, 42: 31-36, 1995.
23. Cip1/Waf1 on growth and differentiation in human colon carcinoma cells. Oncogene, 18: 103-115, 1999.
24. Novick, D., Cohen, B., and Rubinstein, M. The human interferon α/β receptor: characterization and molecular cloning. Cell, 77: 391-400, 1994.
25. Domanski, P., Witte, M., Kellum, M., Rubinstein, M., Hackett, R., Pitha, P., and Colamonici, O. R. Cloning and expression of a long form of the β subunit of the interferon αβ receptor that is required for signaling. J. Biol. Chem., 270: 21606-21611, 1995.
26. Yamamoto, H., Soh, J. W., Monden, T., Klein, M. G., Zhang, L. M., Shirin, H., Arber, N., Tomita, N., Schieren, I., Stein, C. A., and Weinstein, I. B. Paradoxical increase in retinoblastoma protein in colorectal carcinomas may protect cells from apoptosis. Clin. Cancer Res., 5: 1805-1815, 1999.
27. Berenbaum, M. C. Synergy, additivism and antagonism in immunosuppression. A critical review. Clin. Exp. Immunol., 28: 1-18, 1977.
28. Berenbaum, M. C. A method for testing for synergy with any number of agents. J. Infect. Dis., 137: 122-130, 1978.
29. Fraile, R. J., Baker, L. H., Buroker, T. R., Horwitz, J., and Vaitkevicius, V. K. Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Res., 40: 2223-2228, 1980.
30. kip1. Proc. Natl. Acad. Sci. USA, 95: 15158-15160, 1998.
31. kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am. J. Pathol., 154: 313-323, 1999.
32. KIP1 in multistage colorectal carcinogenesis. Cancer Res., 58: 114-122, 1998.
33. Ito, Y., Matsuura, N., Sakon, M., Miyoshi, E., Noda, K., Takeda, T., Umeshita, K., Nagano, H., Nakamori, S., Dono, K., Tsujimoto, M., Nakahara, M., Nakao, K., Taniguchi, N., and Monden, M. Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence. Hepatology, 30: 90-99, 1999.
34. Sangfelt, O., Erickson, S., Castro, J., Heiden, T., Gustafsson, A., Einhorn, S., and Grander, D. Molecular mechanisms underlying interferon-α-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins. Oncogene, 18: 2798-2810, 1999.
35. Sokawa, Y., Watanabe, Y., Watanabe, Y., and Kawade, Y. Interferon suppresses the transition of quiescent 3T3 cells to a growing state. Nature (Lond.), 268: 236-238, 1977.
36. Zhang, K., and Kumar, R. Interferon-α inhibits cyclin E- and cyclin D1-dependent CDK-2 kinase activity associated with RB protein and E2F in Daudi cells. Biochem. Biophys. Res. Commun., 200: 522-528, 1994.
37. Sato, Y., Itoh, F., Hareyama, M., Satoh, M., Hinoda, Y., Seto, M., Ueda, R., and Imai, K. Association of cyclin D1 expression with factors correlated with tumor progression in human hepatocellular carcinoma. J. Gastroenterol., 34: 486-493, 1999.
38. Yano, H., Iemura, A., Haramaki, M., Ogasawara, S., Takayama, A., Akiba, J., and Kojiro, M. Interferon a receptor expression and growth inhibition by interferon α in human liver cancer cell lines. Hepatology, 29: 1708-1717, 1999.
39. Fukuda, R., Ishimura, N., Ishihara, S., Tokuda, A., Satoh, S., Sakai, S., Akagi, S., Watanabe, M., and Fukumoto, S. Expression of interferon-α receptor mRNA in the liver in chronic liver diseases associated with hepatitis C virus: relation to effectiveness of interferon therapy. J. Gastroenterol., 31: 806-811, 1996.
40. Dinney, C. P., Bielenberg, D. R., Perrotte, P., Reich, R., Eve, B. Y., Bucana, C. D., and Fidler, I. J. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-α administration. Cancer Res., 58: 808-814, 1998.
41. Makower, D., Wadler, S., Haynes, H., and Schwartz, E. L. Interferon induces thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in vivo. Clin. Cancer Res., 3: 923-929, 1997.
42. Singh, R. K., Gutman, M., Bucana, C. D., Sanchez, R., Llansa, N., and Fidler, I. J. Interferons a and β down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc. Natl. Acad. Sci. USA, 92: 4562-4566, 1995.